Viewing Study NCT00422812



Ignite Creation Date: 2024-05-05 @ 5:18 PM
Last Modification Date: 2024-10-26 @ 9:30 AM
Study NCT ID: NCT00422812
Status: COMPLETED
Last Update Posted: 2018-01-25
First Post: 2007-01-12

Brief Title: Staccato Prochlorperazine in Migraine Out Patient
Sponsor: Alexza Pharmaceuticals Inc
Organization: Alexza Pharmaceuticals Inc

Study Overview

Official Title: A Multi-center Randomized Double-Blind Placebo-Controlled Single Dose Efficacy and Safety Outpatient Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache
Status: COMPLETED
Status Verified Date: 2008-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Staccato Prochlorperazine is being developed to treat patients suffering from acute migraine headaches In October 2005 we completed a 75 patient multi-center double-blind placebo-controlled Phase 2A clinical trial in patients suffering from moderate to severe acute migraine headaches This Phase 2B clinical trial of Staccato Prochlorperazine has been initiated to assess the efficacy and safety in outpatients with migraine headache with or without aura
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None